doi: 10.1155/2024/9785671.
eCollection 2024.
Retracted: Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study
- PMID: 38549982
- PMCID: PMC10977187
- DOI: 10.1155/2024/9785671
Item in Clipboard
Retracted: Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study
Biomed Res Int.
.
Abstract
[This retracts the article DOI: 10.1155/2020/3208391.].
Copyright © 2024 BioMed Research International.
Retraction of
-
Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study.Biomed Res Int. 2020 May 2;2020:3208391. doi: 10.1155/2020/3208391. eCollection 2020. Biomed Res Int. 2020. Retraction in: Biomed Res Int. 2024 Mar 20;2024:9785671. doi: 10.1155/2024/9785671. PMID: 32461977 Free PMC article. Retracted.
Similar articles
-
Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study.Biomed Res Int. 2020 May 2;2020:3208391. doi: 10.1155/2020/3208391. eCollection 2020. Biomed Res Int. 2020. Retraction in: Biomed Res Int. 2024 Mar 20;2024:9785671. doi: 10.1155/2024/9785671. PMID: 32461977 Free PMC article. Retracted.
-
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.Clin Cancer Res. 2007 Jan 1;13(1):228-33. doi: 10.1158/1078-0432.CCR-06-1345. Clin Cancer Res. 2007. PMID: 17200359 Clinical Trial.
-
Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.Clin Breast Cancer. 2015 Jun;15(3):191-6. doi: 10.1016/j.clbc.2014.12.003. Epub 2014 Dec 24. Clin Breast Cancer. 2015. PMID: 25579459 Clinical Trial.
-
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial.Anticancer Res. 2019 Apr;39(4):2053-2059. doi: 10.21873/anticanres.13316. Anticancer Res. 2019. PMID: 30952749 Clinical Trial.
-
Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.Cancer. 2010 Jun 15;116(12):2856-67. doi: 10.1002/cncr.25120. Cancer. 2010. PMID: 20564392 Review.
References
-
- Zhang M., Li L., Zhang S., et al. Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Carcinoma: A Real-World Study. BioMed Research International . 2020;2020:9. doi: 10.1155/2020/3208391.3208391 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
